The authors performed transcriptomic bioinformatic analyses using publicly available COPD datasets (GSE11952 and GSE232805) to uncover genes and pathways linked to neutrophil‑driven oxidative stress in chronic obstructive pulmonary disease (COPD). Network analysis and multiple centrality algorithms were applied to prioritize hub genes. The top‑ranked genes common across the centrality measures were FN1, CD44, ITGA5, and THBS1. These hub nodes were associated with processes relevant to COPD pathogenesis, including extracellular matrix–receptor interactions and signalling cascades related to inflammation and cell stress.
Following hub gene identification, the study used molecular docking to evaluate potential interactions between resveratrol and the protein products of prioritized genes. Docking results indicated the highest predicted binding affinity between resveratrol and ITGA5, with a reported binding energy of -7.4 kcal/mol. This in‑silico observation supported selection of ITGA5 as a candidate molecular target potentially mediating resveratrol’s effects on neutrophil function and oxidative responses in COPD.
To translate the in‑silico findings into functional data, human peripheral blood neutrophils were isolated from both healthy volunteers and patients with COPD. Isolated neutrophils were challenged ex‑vivo with bacteria or with phorbol 12‑myristate 13‑acetate (PMA) to stimulate oxidative and NET responses. Some experiments included exposure to cigarette smoke extract (CSE) to model smoke‑related neutrophil activation. Resveratrol was administered in the experimental conditions to assess its modulatory effects. Data analyses and exploratory statistics were performed using Python‑based pipelines. The abstract does not report specific sample sizes, resveratrol concentrations, incubation times, or detailed statistical metrics; these parameters are available only in the full text.
Quantitative ex‑vivo measurements revealed that resveratrol significantly attenuated bacterial‑induced production of reactive oxygen species (ROS) in neutrophils from healthy donors and in neutrophils exposed to cigarette smoke extract (CSE). In neutrophils obtained from COPD patients, resveratrol similarly reduced ROS generation in PMA‑stimulated cells. These findings indicate that resveratrol exerts antioxidant activity at the level of primary human neutrophils under multiple activating conditions relevant to COPD pathophysiology.
In addition to reducing ROS, resveratrol demonstrated significant efficacy in decreasing neutrophil extracellular trap (NET) formation in PMA‑stimulated neutrophils from COPD patients. The combined reduction in both ROS and NET formation suggests resveratrol can modulate neutrophil effector functions that are implicated in tissue damage, mucus alteration, and persistent inflammation in COPD.
The hub genes highlighted by the bioinformatic analysis—FN1, CD44, ITGA5, and THBS1—map to pathways implicated in COPD biology. Reported pathway associations include extracellular matrix–receptor interaction, advanced glycation end‑products (AGE)–receptor signalling, hypoxia‑inducible factor 1 (HIF‑1) signalling, cytokine signalling, and ferroptosis. These pathways are relevant to lung remodelling, inflammation, hypoxic responses, and regulated forms of oxidative cell death, providing a plausible mechanistic context for how modulation of integrin‑related signalling (for example via ITGA5) could influence neutrophil oxidative behaviour.
Taken together, the integrated bioinformatics and ex‑vivo data support a model in which resveratrol reduces neutrophil‑driven oxidative stress and NET formation in COPD, with ITGA5 identified as a candidate molecular target mediating these effects. The findings suggest resveratrol may have therapeutic potential as an antioxidant modulator in COPD by dampening neutrophil effector functions that contribute to disease progression.
Limitations reported in the abstract are minimal. Specific experimental details—such as sample sizes, participant characteristics, exact resveratrol dosing, statistical effect sizes, and long‑term or in‑vivo outcomes—were not provided in the abstract and would require examination of the full publication for comprehensive assessment. The study used ex‑vivo and in‑silico approaches; translation to clinical efficacy and safety in COPD patients will require controlled in‑vivo and clinical studies.
This study provides combined computational and ex‑vivo experimental evidence that resveratrol can attenuate ROS production and NET formation in human neutrophils relevant to COPD, and identifies ITGA5 as a potential target for these effects. Further detailed methodological information and clinical validation are needed to determine translational potential.